Pfenex extends contract with Glide Technologies

Glide Technologies will continue to develop an alternate delivery method of a recombinant protective antigen developed by PFEnex as part of a subcontract extension with the company that was recently announced. 

Pfenex's compound is a vaccine candidate against the anthrax infection that utilizes solid dose formulation methods from Glide technologies.

The contract extension comes after the National Institute of Allergy and Infectious Disease (NIAID) extended its own contract with PFEnex for development of the vaccine. 

"Following encouraging stability data with initial formulations, we are pleased that NIAID continues to fund the progression of this program," Glide CEO Dr. Mark Carnegie-Brown said. "We believe that a combination of Pfenex's proprietary rPA-based anthrax vaccine and Glide's novel formulations and delivery technology will address key issues with current products designed for a response to an anthrax bio-threat."

This contract extension follows initial positive results and data from research on methodologies of delivering the vaccine candidate along with continued funding from NIAID.

Glide Technologies specializes in solid dose formulations for medical treatments and preventative vaccines. Its SDI injector has shown potential to enhance long-term therapeutics and an improved immune response in the case of vaccines. Currently this technology is being utilized in parathyroid hormone injection, vaccine candidates for anthrax and influenza, and for octreotide injections. The company is also researching and developing non-invasive diagnostic tools.

Organizations in this Story


Want to get notified whenever we write about Pfenex ?
Next time we write about Pfenex, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.